Eleonora A M L Mutsaerts1,2,3, Marta C Nunes1,2, Martijn N van Rijswijk1,2,3, Kerstin Klipstein-Grobusch3,4, Kennedy Otwombe5, Mark F Cotton6, Avy Violari5, Shabir A Madhi1,2. 1. Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa. 2. Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa. 3. Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, the Netherlands. 4. Division of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg. 5. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg. 6. Family Clinical Research Unit, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Abstract
BACKGROUND:Human immunodeficiency virus (HIV)-infected and HIV-exposed-uninfected (HEU) children may be at increased risk of measles infection due to waning of immunity following vaccination. We evaluated persistence of antibodies to measles vaccination at 4.5 years of age in HIV-unexposed, HEU, and HIV-infected children with CD4+ ≥25% previously randomized to immediate antiretroviral therapy (ART) interrupted at 12 months (HIV/Immed-ART-12), 24 months (HIV/Immed-ART-24), or when clinically/immunologically indicated (HIV/Def-ART). The HIV/Def-ART group initiated ART by median 5.8 (interquartile range, 4.4-10.3) months of age. METHODS: In this study, HIV-unexposed (n = 95), HEU (n = 84), HIV/Immed-ART-12 (n = 70), HIV/Immed-ART-24 (n = 70), and HIV/Def-ART (n = 62) children were scheduled to receive measles vaccination at age 9 and 15-18 months. Antimeasles serum immunoglobulin G titers were quantified using enzyme-linked immunosorbent assay at 4.5 years. RESULTS: Compared with HIV-unexposed children (2860 mIU/mL), measles antibodygeometric mean titers (GMTs) were significantly lower in both HIV/Immed-ART-12 (571; P < .001) and HIV/Immed-ART-24 (1136; P < .001) but similar in the HIV/Def-ART (2777) and HEU (3242) groups. Furthermore, compared with HIV-unexposed, antibody titers ≥330 mIU/mL (ie, presumed serocorrelate for protection; 99%) were also significantly lower in HIV/Immed-ART-12 (70%; P < .001) and HIV/Immed-ART-24 (83%; P < .001) but similar in the HIV/Def-ART (90%) and HEU (98%) groups. CONCLUSIONS: HIV-infected children in whom ART was interrupted at either 12 or 24 months had lower GMTs and lower proportions with seroprotective titers than HIV-unexposed children, indicating a potential downside of ART treatment interruption. CLINICAL TRIALS REGISTRATION: NCT00099658 and NCT00102960.
RCT Entities:
BACKGROUND: Human immunodeficiency virus (HIV)-infected and HIV-exposed-uninfected (HEU) children may be at increased risk of measles infection due to waning of immunity following vaccination. We evaluated persistence of antibodies to measles vaccination at 4.5 years of age in HIV-unexposed, HEU, and HIV-infectedchildren with CD4+ ≥25% previously randomized to immediate antiretroviral therapy (ART) interrupted at 12 months (HIV/Immed-ART-12), 24 months (HIV/Immed-ART-24), or when clinically/immunologically indicated (HIV/Def-ART). The HIV/Def-ART group initiated ART by median 5.8 (interquartile range, 4.4-10.3) months of age. METHODS: In this study, HIV-unexposed (n = 95), HEU (n = 84), HIV/Immed-ART-12 (n = 70), HIV/Immed-ART-24 (n = 70), and HIV/Def-ART (n = 62) children were scheduled to receive measles vaccination at age 9 and 15-18 months. Antimeasles serum immunoglobulin G titers were quantified using enzyme-linked immunosorbent assay at 4.5 years. RESULTS: Compared with HIV-unexposed children (2860 mIU/mL), measles antibody geometric mean titers (GMTs) were significantly lower in both HIV/Immed-ART-12 (571; P < .001) and HIV/Immed-ART-24 (1136; P < .001) but similar in the HIV/Def-ART (2777) and HEU (3242) groups. Furthermore, compared with HIV-unexposed, antibody titers ≥330 mIU/mL (ie, presumed serocorrelate for protection; 99%) were also significantly lower in HIV/Immed-ART-12 (70%; P < .001) and HIV/Immed-ART-24 (83%; P < .001) but similar in the HIV/Def-ART (90%) and HEU (98%) groups. CONCLUSIONS:HIV-infectedchildren in whom ART was interrupted at either 12 or 24 months had lower GMTs and lower proportions with seroprotective titers than HIV-unexposed children, indicating a potential downside of ART treatment interruption. CLINICAL TRIALS REGISTRATION: NCT00099658 and NCT00102960.
Authors: Shabir A Madhi; Peter Adrian; Mark F Cotton; James A McIntyre; Patrick Jean-Philippe; Shawn Meadows; Sharon Nachman; Helena Käyhty; Keith P Klugman; Avye Violari Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226
Authors: Elvis B Kidzeru; Anneke C Hesseling; Jo-Ann S Passmore; Landon Myer; Hoyam Gamieldien; Christophe Toukam Tchakoute; Clive M Gray; Donald L Sodora; Heather B Jaspan Journal: AIDS Date: 2014-06-19 Impact factor: 4.177
Authors: William J Moss; Susana Scott; Nanthalile Mugala; Zaza Ndhlovu; Judy A Beeler; Susette A Audet; Mirriam Ngala; Sheila Mwangala; Chansa Nkonga-Mwangilwa; Judith J Ryon; Mwaka Monze; Francis Kasolo; Thomas C Quinn; Simon Cousens; Diane E Griffin; Felicity T Cutts Journal: J Infect Dis Date: 2007-06-19 Impact factor: 5.226
Authors: Brian A Reikie; Shalena Naidoo; Candice E Ruck; Amy L Slogrove; Corena de Beer; Heleen la Grange; Rozanne C M Adams; Kevin Ho; Kinga Smolen; David P Speert; Mark F Cotton; Wolfgang Preiser; Monika Esser; Tobias R Kollmann Journal: Clin Vaccine Immunol Date: 2012-10-31
Authors: Li Liu; Shefali Oza; Dan Hogan; Yue Chu; Jamie Perin; Jun Zhu; Joy E Lawn; Simon Cousens; Colin Mathers; Robert E Black Journal: Lancet Date: 2016-11-11 Impact factor: 79.321